Short answer
Cryoport, Inc. (CYRX) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026 announced May 4, 2026.
Cryoport, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026 announced May 4, 2026
- Financial results and management commentary contained in Exhibit 99.1 press release
- Disclosure furnished under Item 2.02, generally outside Section 18 filing liability
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue rose 16% to $47.8M, with Services up 18% and Products up 15%, confirming broad-based demand
- Commercial CGT revenue increased 26% to $9.1M, supported by 21 approved therapies and 766 clinical trials
- Adjusted EBITDA loss narrowed to $0.6M from $2.8M, but GAAP continuing-operations loss widened to $9.4M
- Full-year 2026 revenue guidance raised to $192M-$196M, signaling stronger visibility after the first quarter
- $403.6M in cash, equivalents, and short-term investments supports planned Paris and Santa Ana capacity expansions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cryoport, Inc. 8-K filings
Get the next CYRX 8-K as it lands
Follow CYRX for push alerts, or ask the research agent what this filing means.